Pallas Capital Advisors LLC Boosts Stock Position in Teleflex Incorporated $TFX

Pallas Capital Advisors LLC grew its position in shares of Teleflex Incorporated (NYSE:TFX) by 196.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,257 shares of the medical technology company’s stock after purchasing an additional 8,116 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Teleflex were worth $1,500,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TFX. MassMutual Private Wealth & Trust FSB boosted its stake in Teleflex by 57.9% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after buying an additional 77 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Teleflex by 17.5% during the second quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company’s stock worth $148,000 after acquiring an additional 186 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of Teleflex by 248.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock worth $34,000 after acquiring an additional 199 shares during the last quarter. Empowered Funds LLC boosted its stake in shares of Teleflex by 15.8% in the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after purchasing an additional 230 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Teleflex by 2.1% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 11,345 shares of the medical technology company’s stock valued at $1,343,000 after purchasing an additional 231 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Wall Street Analysts Forecast Growth

TFX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Royal Bank Of Canada restated a “sector perform” rating and set a $135.00 price target on shares of Teleflex in a research report on Wednesday, December 17th. Needham & Company LLC upgraded Teleflex from a “hold” rating to a “buy” rating and set a $138.00 price objective for the company in a research report on Tuesday, January 27th. Truist Financial increased their price objective on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research note on Thursday, December 18th. Finally, Wells Fargo & Company decreased their target price on shares of Teleflex from $139.00 to $116.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teleflex has a consensus rating of “Hold” and an average price target of $139.00.

Teleflex Price Performance

Shares of Teleflex stock opened at $103.78 on Tuesday. The business has a 50 day moving average of $113.64 and a 200 day moving average of $118.88. Teleflex Incorporated has a 52 week low of $100.18 and a 52 week high of $180.58. The company has a market cap of $4.59 billion, a PE ratio of -14.12, a P/E/G ratio of 1.35 and a beta of 0.92. The company has a quick ratio of 1.53, a current ratio of 2.57 and a debt-to-equity ratio of 0.67.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.